Phase II Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG/NCI Experience: Invasive Mucinous or Non-mucinous Lepidic Adenocarcinoma of the Lung (formerly Bronchioloalveolar Carcinoma)

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2024 Nov 25

PMID 39583952

Authors

Young Kwang Chae

Megan Othus

Sandip Pravin Patel

David E Gerber

Tawee Tanvetyanon

Hye Sung Kim

Liam Il-Young Chung

Christine M McLeod

Gabby Lopez

Helen X Chen

Elad Sharon

Howard Streicher

Cristopher W Ryan

Charles D Blanke

Razelle Kurzrock

Affiliations

Soon will be listed here.

Abstract

Background: Anti-programmed death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies.

Objectives: This study presents the first results of ipilimumab-nivolumab in invasive mucinous or non-mucinous lepidic adenocarcinoma (invasive mucinous adenocarcinoma (IMA) or invasive non-mucinous lepidic adenocarcinomas (INLA), respectively) of the lung.

Design: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) is a prospective, open-label, multicenter (1016 US sites), multi-cohort phase II trial of ipilimumab (1 mg/kg intravenously (IV) every 6 weeks) plus nivolumab (240 mg IV every 2 weeks).

Methods: Participants histologically diagnosed with advanced IMA or INLA, who had not responded to at least one line of therapy, were included in the bronchioloalveolar carcinoma cohort. The primary endpoint was the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (confirmed complete and partial responses (CR and PR)). Secondary endpoints were progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; stable disease (SD) ⩾ 6 months plus ORR), and toxicity.

Results: Eight evaluable patients (median age: 77 years; the number of prior therapies ranged from 0 to 4; one patient with prior exposure to a PD-1 inhibitor; comprising six IMA and two INLA) were treated. One IMA had a 40% regression (PFS 45.2+ months, PD-L1 0%, KRAS G12C mutated, tumor mutational burden [TMB] 13 mut/Mb). One INLA had 66% regression (PFS 23.8 months, PD-L1 unknown, no actionable mutations, TMB 3 mut/Mb). Overall ORR was 25.0% (2/8) and CBR, 62.5% (5/8); PFS for the patients with SD > 6 months was 43.4+, 11.7+, and 8.3 months. The median PFS was 16 months (5.3-not reached) and the median OS was 32.2 months (14.6-not reached). The toxicity profile was similar to previous reports.

Conclusion: Ipilimumab plus nivolumab in the bronchioloalveolar carcinoma cohort (IMA, INLA) resulted in a durable ORR of 25.0% and CBR of 62.5% (PFS, 8.3 11.7+. 23.8 (PR), 43.4+ and 45.2+ (PR) months). Correlative studies to determine response and resistance markers are ongoing. Expanded prospective studies are warranted.

Trial Registration: ClinicalTrials.gov registry: NCT02834013.

References

Lin G, Li H, Kuang J, Tang K, Guo Y, Han A . Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung. Am J Clin Pathol. 2018; 149(5):373-378. DOI: 10.1093/ajcp/aqx170. View

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F . Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2012; 8(1):52-61. DOI: 10.1097/JTO.0b013e3182769aa8. View

Cui D, Xie S, Liu Q . Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma. BMC Pulm Med. 2023; 23(1):9. PMC: 9830770. DOI: 10.1186/s12890-023-02305-x. View

Muller S, Mayer S, Moller P, Barth T, Marienfeld R . Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma. Neoplasia. 2021; 23(6):584-593. PMC: 8190489. DOI: 10.1016/j.neo.2021.05.005. View

Gay N, Wang Y, Beadling C, Warrick A, Neff T, Corless C . Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions. J Thorac Oncol. 2017; 12(8):e107-e110. DOI: 10.1016/j.jtho.2017.04.025. View

Patel S, Othus M, Chae Y, Dennis M, Gordon S, Mutch D . A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Clin Cancer Res. 2023; 30(1):33-38. PMC: 10842092. DOI: 10.1158/1078-0432.CCR-23-2293. View

Cheema P, Doherty M, Tsao M . A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. J Thorac Oncol. 2017; 12(12):e200-e202. DOI: 10.1016/j.jtho.2017.07.033. View

Butcher N, Monsour A, Mew E, Chan A, Moher D, Mayo-Wilson E . Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022; 328(23):2345-2356. DOI: 10.1001/jama.2022.21243. View

Jang Y, Hyun D, Choi C, Lee D, Kim S, Yoon S . Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. BMC Cancer. 2021; 21(1):731. PMC: 8235206. DOI: 10.1186/s12885-021-08472-6. View

10.

Patel S, Mayerson E, Chae Y, Strosberg J, Wang J, Konda B . A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021; 127(17):3194-3201. PMC: 8606104. DOI: 10.1002/cncr.33591. View

11.

Hellmann M, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S, Carcereny Costa E . Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019; 381(21):2020-2031. DOI: 10.1056/NEJMoa1910231. View

12.

Bagchi S, Yuan R, Engleman E . Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2020; 16:223-249. DOI: 10.1146/annurev-pathol-042020-042741. View

13.

Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R . Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. Cancers (Basel). 2018; 10(12). PMC: 6316015. DOI: 10.3390/cancers10120478. View

14.

Shim H, Kenudson M, Zheng Z, Liebers M, Cha Y, Hoang Ho Q . Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2015; 10(8):1156-62. DOI: 10.1097/JTO.0000000000000579. View

15.

Iwai S, Funasaki A, Sekimura A, Motono N, Usuda K, Yamada S . Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report. Ann Med Surg (Lond). 2020; 56:82-85. PMC: 7320235. DOI: 10.1016/j.amsu.2020.05.021. View

16.

Akhtar Z, Laageide L, Robles J, Winters C, Wall G, Mallen J . Unusual presentation of lepidic adenocarcinoma in a healthy female. BMC Pulm Med. 2022; 22(1):197. PMC: 9109452. DOI: 10.1186/s12890-022-01969-1. View

17.

Kadota K, Yeh Y, DAngelo S, Moreira A, Kuk D, Sima C . Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014; 38(8):1118-27. PMC: 4666292. DOI: 10.1097/PAS.0000000000000246. View

18.

DeSantis C, Kramer J, Jemal A . The burden of rare cancers in the United States. CA Cancer J Clin. 2017; 67(4):261-272. DOI: 10.3322/caac.21400. View

19.

Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E . EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J. 2013; 43(3):872-83. DOI: 10.1183/09031936.00018013. View

20.

Wagner M, Othus M, Patel S, Ryan C, Sangal A, Powers B . Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021; 9(8). PMC: 8330584. DOI: 10.1136/jitc-2021-002990. View